Business ❯ Employment ❯ Workforce Reduction ❯ Job Offers

Adaptimmune Employees

Adaptimmune Sells Tecelra and Late-Stage Cell Therapies to U.S. WorldMeds for $55M

Adaptimmune retains its two preclinical T cell therapies after selling Tecelra plus two clinical-stage programs in a $55 million deal that shifts commercialization staff to U.S. WorldMeds.